Treatment Information

Back

Melanoma treatment details. Chemotherapy.

Mayo Clinic, Rochester, MN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Rochester, MN
Treatments:ChemotherapyHospital:Mayo Clinic
Drugs:Journal:Link
Date:Jun 2005

Description:

Patients: This Phase II study involved 27 patients with metastatic malignant melanoma. Eighteen patients were men, and nine were women. The median age was 56. Metastatic sites included lymph nodes, liver, and lung.

Treatment: The treatment consisted of one chemotherapeutic agent: Bortezomib.

Toxicity: Grade 3 toxicities included sensory neuropathy, thrombocytopenia, constipation, fatigue, ileus, abdominal pain, and infection without neutropenia.

Results: The median overall survival was 14.5 months.
The authors however concluded, brotezomib "was not found to be effective in the treatment of patients with metastatic melanoma".

Correspondence: Svetomir N. Markovic, M.D.




Back